You need three pieces of information: the concentration printed on your vial, the dose your provider prescribed in milligrams, and a simple formula to convert between the two. The formula is: Units = (Dose in mg ÷ Concentration in mg/mL) × 100. Get any of these wrong and you can end up injecting a dramatically higher dose than intended — concentration math shows that common errors (such as confusing a 1 mg/mL chart with a 5 mg/mL vial) can produce five-fold to twenty-fold overdoses. The FDA issued a safety alert describing hospitalizations for dehydration and severe GI events resulting from dosing errors with compounded semaglutide [1]. This article walks you through the measurement process step by step, but it also explains why these errors happen so frequently — and why the measurement problem itself is a symptom of a larger issue with how compounded GLP-1 medications reach patients.

Understanding Your Vial: Concentration Is Everything

Compounded semaglutide comes in multi-dose vials, not the prefilled pens used for FDA-approved versions like Ozempic and Wegovy. The critical difference: with a prefilled pen, the dose is dialed in milligrams and the device delivers it. With a vial, you have to calculate and measure the correct volume yourself using an insulin syringe.

The first thing you must know is the concentration of your specific vial. This is expressed in milligrams per milliliter (mg/mL) and should be printed on the vial label. Common concentrations for compounded semaglutide include:

• 1 mg/mL — lower concentration, requires larger injection volumes
• 2.5 mg/mL — mid-range, commonly prescribed
• 5 mg/mL — higher concentration, requires smaller volumes per dose

This is where the danger starts. The same milligram dose requires a completely different volume depending on the concentration. A 0.5 mg dose from a 1 mg/mL vial requires 50 units (0.5 mL). That same 0.5 mg dose from a 5 mg/mL vial requires only 10 units (0.1 mL). If you draw up 50 units from a 5 mg/mL vial — because that's what your previous vial required — you've just injected 2.5 mg instead of 0.5 mg. That's a five-fold overdose.

Compounded medications do not have standardized concentrations the way FDA-approved products do. Different compounding pharmacies may supply different concentrations, and your concentration can change between refills if your pharmacy adjusts their formulation or you switch pharmacies. Check the label on every new vial. Never assume.

The Math: Converting Milligrams to Units

Standard insulin syringes are marked in units, where 100 units equals 1 milliliter (mL). Your provider prescribes a dose in milligrams (mg). The vial is labeled with a concentration in mg/mL. You need to connect all three.

The formula:

Units to draw = (Prescribed dose in mg ÷ Vial concentration in mg/mL) × 100

Example for a 2.5 mg/mL vial (common concentration):

Example for a 5 mg/mL vial (same doses, half the volume):

Notice that 20 units from a 2.5 mg/mL vial gives you 0.5 mg, but 20 units from a 5 mg/mL vial gives you 1.0 mg — double the dose. This is the single most common source of dosing errors with compounded semaglutide.

If your provider tells you to inject a certain number of "units" without specifying the concentration, or if you receive a new vial with a different concentration than your previous one, do not inject until you've confirmed the correct number of units for your prescribed milligram dose at the new concentration. Call your pharmacy or provider.

Step-by-Step: Drawing and Injecting the Dose

Once you've calculated your dose in units:

1\. Inspect the vial. The liquid should be clear and colorless. If it's cloudy, discolored, or contains particles, do not use it — contact your pharmacy.

2\. Clean the vial top. Wipe the rubber stopper with a sterile alcohol pad. Let it air dry.

3\. Prepare the syringe. Using a standard U-100 insulin syringe, pull the plunger back to draw in air equal to the volume you plan to withdraw. This makes drawing the medication easier and prevents a vacuum in the vial.

4\. Inject air into the vial. Insert the needle through the rubber stopper and push the air in. Keep the needle in the vial.

5\. Invert the vial and draw medication. Turn the vial upside down. Pull the plunger back slowly until the top black line of the plunger aligns with your target unit marking on the syringe barrel. Read the measurement at the top edge of the plunger's rubber tip — not the bottom edge, not the middle.

6\. Remove air bubbles. If you see air bubbles in the syringe, tap the barrel gently to move them to the top, then push the plunger slightly to expel the air. Recheck your volume and adjust if needed.

7\. Choose and clean the injection site. Rotate between the abdomen (at least two inches from the navel), the front of your thighs, and the back of your upper arms. Clean the site with a fresh alcohol pad.

8\. Inject. Pinch the skin at the injection site. Insert the needle at a 90-degree angle. Push the plunger steadily. Count to five or six before withdrawing the needle — this allows the full dose to be deposited under the skin.

9\. Dispose of the needle. Place the used syringe directly into a sharps container. Do not recap, bend, or reuse needles.

The Three Measurement Mistakes That Cause Overdoses

The FDA's July 2024 safety alert identified specific error patterns that led to patients being hospitalized after injecting compounded semaglutide \[1\]. Understanding these patterns is more protective than memorizing any dosing chart.

Mistake 1: Confusing units, milliliters, and milligrams. These are three different measurement systems. Units are markings on the syringe. Milliliters are a volume. Milligrams are a weight of drug. When a provider says "inject 0.5" and doesn't specify the unit, a patient might draw 0.5 mL (50 units) when the intended dose was 0.5 mg (which might be 10 or 20 units depending on concentration). Based on the concentration math, the result can be a five-fold to twenty-fold overdose depending on the vials involved.

Mistake 2: Using the wrong dosing chart for your concentration. Dosing charts circulate online and are sometimes included with compounded products. But a chart calibrated for a 2.5 mg/mL vial gives dangerously wrong numbers when applied to a 5 mg/mL vial — every dose would be doubled. Always verify that the concentration on any dosing chart matches the concentration on your vial.

Mistake 3: Escalating without guidance. The standard semaglutide titration schedule — 0.25 mg for four weeks, then 0.5 mg, then 1.0 mg, and so on — exists because tolerance to GI side effects builds gradually. Some patients, frustrated with slow weight loss or misunderstanding the schedule, jump ahead in the titration. With a compounded vial and syringe, nothing physically prevents you from drawing a higher dose. With a prefilled pen, the dose is limited by the device.

The FDA reported that dosing errors led to adverse events including severe nausea, vomiting, abdominal pain, fainting, and dehydration — with some patients requiring hospitalization \[1\]. Separately, acute pancreatitis and gallstones are recognized risks of GLP-1 medications as a class, and while they were reported in the context of compounded semaglutide use, they are not specifically attributed to measurement errors by the FDA alert.

Why This Problem Doesn't Exist with FDA-Approved Pens

FDA-approved semaglutide products — Ozempic for diabetes, Wegovy for weight management — come in prefilled injection pens. You dial your dose in milligrams, press the button, and the pen delivers it. There is no vial, no syringe, no concentration calculation, and no opportunity to draw five times the intended dose because you confused units with milligrams.

The pens are also standardized. Every Wegovy 0.25 mg pen delivers exactly 0.25 mg. There's no concentration variation between batches, no compounding pharmacy differences, and no degraded potency from non-validated formulations.

This isn't a minor convenience difference — it's a fundamental safety design. The pen eliminates an entire category of medication error. The FDA's dosing error alert was specifically about compounded products in multi-dose vials, not about FDA-approved pens \[1\].

The trade-off, of course, is cost and access. FDA-approved semaglutide products are expensive, often exceeding $1,000 per month without insurance coverage. Compounded semaglutide has been significantly cheaper, which is why millions of patients have used it. But the lower price comes with real measurement and quality risks that the approved products don't carry.

What the FDA Has Warned About — Beyond Dosing Errors

Dosing errors are one concern. The broader FDA warnings about compounded semaglutide go further.

As of July 2025, the FDA had received 605 adverse event reports associated with compounded semaglutide and 545 reports associated with compounded tirzepatide \[2\]. The agency explicitly notes these numbers are likely underreported because many state-licensed compounding pharmacies are not required to submit adverse event reports.

The specific concerns include:

• Salt form differences. The FDA has warned that some compounding pharmacies use semaglutide sodium or semaglutide acetate — salt forms that are technically different active ingredients from the semaglutide base used in FDA-approved products \[2\]. The clinical significance of this difference is not fully characterized, but it means the product you're measuring may not behave identically to what was studied in clinical trials.
• Potency variability. Without the validated manufacturing processes required for FDA-approved drugs, compounded products can vary in actual drug concentration between batches. Your "5 mg/mL" vial may not contain exactly 5 mg/mL — and if it's more concentrated than labeled, your careful measurement still delivers the wrong dose.
• Sterility failures. Multi-dose vials require sterile technique every time you draw a dose. Compounded products from facilities without rigorous quality controls have been associated with contamination risks.

None of this means compounded semaglutide is guaranteed to be dangerous. Many compounding pharmacies produce high-quality products. But the patient has no way to independently verify concentration accuracy, sterility, or stability — risks that don't exist with FDA-approved products manufactured under GMP (Good Manufacturing Practice) standards.

Storage Matters More Than You Think

Semaglutide is a protein-based injectable that degrades when improperly stored. The general guidance for compounded products:

• Refrigerate at 36-46°F (2-8°C) before first use
• After first use, follow the specific storage instructions from your compounding pharmacy — some formulations require continued refrigeration, while others allow limited room-temperature storage
• Never freeze. Frozen and thawed semaglutide may lose potency without any visible change in the solution
• Protect from light and heat. Don't leave vials in a car, near a window, or in a bathroom medicine cabinet where heat and humidity fluctuate

A degraded product that appears normal but has reduced potency creates a paradoxical risk: it seems ineffective, prompting either dose escalation or frustration with treatment — and when you switch to a fresh, fully potent vial, the higher dose you've been taking suddenly becomes an overdose.

The Bigger Question: Should You Be Measuring at All?

This article explains how to measure compounded semaglutide correctly. But it's worth stepping back and asking whether self-measuring from a multi-dose vial is the right approach for you.

JumpstartMD prescribes FDA-approved GLP-1 medications — Wegovy, Ozempic, Mounjaro, Zepbound — delivered in prefilled pens that eliminate the measurement problem entirely. Beyond the device, the clinical difference is structural: patients receive hands-on injection training, their dose is managed through a clinician-guided titration schedule, and the products are manufactured under FDA-validated processes with standardized concentrations. The compounding pharmacy risks described above — salt form differences, potency variability, sterility concerns, and the measurement errors that have led to FDA warnings — simply don't apply.

The peptides used by JumpstartMD are "carefully sourced and vetted," and clinicians select the appropriate product matched to each patient's clinical profile, specify a stepwise titration schedule, and provide clear protocols for missed doses and restarts. This structured approach is fundamentally different from receiving a vial, a bag of syringes, and a dosing chart — and being left to calculate and inject on your own.

If you're currently using compounded semaglutide and want to transition to FDA-approved products with clinical oversight, or if you're considering starting GLP-1 treatment and want to avoid the compounding risks altogether, call 408.478.3496.

Frequently Asked Questions

Q: My provider told me to inject "20 units." How do I know what dose that is in milligrams? A: You need to know the concentration of your vial. For a 2.5 mg/mL vial, 20 units equals 0.5 mg. For a 5 mg/mL vial, 20 units equals 1.0 mg. The same number of units delivers a completely different milligram dose depending on concentration. If your provider told you to inject a certain number of units, confirm which concentration they were referencing — and verify it matches the vial you have.

Q: Can I use any insulin syringe? A: Use a standard U-100 insulin syringe, where 100 units equals 1 mL. These are the most widely available and what your dosing calculations are based on. Avoid U-40 or U-500 syringes — they have different unit-to-volume ratios and will result in incorrect doses. Check the syringe packaging to confirm it says "U-100."

Q: What should I do if I think I injected too much? A: Contact your provider or go to urgent care or an emergency room. Symptoms of overdose include severe nausea, persistent vomiting, abdominal pain, fainting, and signs of dehydration (dark urine, dizziness, rapid heartbeat). Do not wait to see if symptoms develop — semaglutide's effects can intensify over hours due to its long absorption profile. Bring your vial and syringe so the clinical team can assess what dose you likely received.

Q: My new vial has a different concentration than my last one. What do I do? A: Recalculate your dose in units using the formula: Units = (Dose in mg ÷ New concentration in mg/mL) × 100. Do not draw the same number of units as before. If you're unsure, call your compounding pharmacy or provider before injecting. This concentration change between refills is one of the most common sources of dosing errors.

Q: Why doesn't my compounding pharmacy include a dosing chart? A: Some do, some don't. Compounded medications are not required to include the standardized labeling and patient instructions that FDA-approved products carry \[2\]. If your vial arrives without clear dosing instructions specific to its concentration, contact your pharmacy before using it. Do not rely on dosing charts found online unless you've confirmed they match your exact concentration.

Q: Is compounded semaglutide the same as Ozempic or Wegovy? A: Not exactly. The active ingredient is intended to be the same, but compounded versions may use different salt forms (semaglutide sodium or acetate rather than semaglutide base), are manufactured under different quality standards, and come in multi-dose vials rather than prefilled pens \[2\]. The FDA has not evaluated compounded semaglutide for safety or efficacy. The clinical trial data supporting semaglutide's benefits applies to the FDA-approved formulations, not to compounded versions.

Conclusion

Measuring compounded semaglutide correctly requires knowing your vial's concentration, using the right formula, and reading the syringe carefully at every injection. The math isn't complicated, but the consequences of getting it wrong are serious — concentration math shows that common measurement errors can produce five-fold to twenty-fold overdoses, and the FDA has documented hospitalizations resulting from such errors \[1\]. If you're using compounded semaglutide, verify your concentration on every new vial, use the formula (Units = Dose in mg ÷ Concentration × 100), and never assume that the same number of units means the same milligram dose when your concentration changes. And if the measurement burden feels like a risk you'd rather not carry, FDA-approved prefilled pens eliminate that entire category of error.

References

\[1\] U.S. Food and Drug Administration, "FDA's concerns with unapproved GLP-1 drugs used for weight loss," updated Feb. 2026. \[Accessed: Feb. 11, 2026\].

\[2\] U.S. Food and Drug Administration, "FDA alerts health care professionals about dosing errors associated with compounded semaglutide," July 2024. \[Accessed: Feb. 11, 2026\].